

One-Pot Synthesis of Imidazole-4-Carboxylates by Microwave-Assisted 1,5-Electrocyclization of Azavinyl Azomethine Ylides

Lisa Preti,^[a] Orazio A. Attanasi,^[b] Emilia Caselli,^[a] Gianfranco Favi,^[b] Claudia Ori,^[a] Paolo Davoli,^[a] Fulvia Felluga,^[c] and Fabio Prati^{*[a]}

Keywords: Azomethine ylides / Electrocyclic reactions / Microwave chemistry / Multicomponent reactions / Nitrogen heterocycles

Diversely functionalized imidazole-4-carboxylates were synthesized by microwave-assisted 1,5-electrocyclization of 1,2-diaza-1,3-diene-derived azavinyl azomethine ylides. 1,2-Diaza-1,3-dienes were treated with primary aliphatic or aromatic amines and subjected to microwave irradiation in the

presence of aldehydes. 3-Alkyl- and 3-arylimidazole-4-carboxylates were prepared in good yields through a one-pot multicomponent procedure. Modulation of the substituents at C-2, N-3, and C-5 was possible, and 2-unsubstituted imidazoles were obtained when paraformaldehyde was used.

Introduction

The field of organic synthesis has witnessed a dramatic surge in the application of microwave irradiation as an alternative to conventional heating. In most cases, microwave heating has resulted in drastic reduction of reaction times, improvement of workup procedures, and, ultimately, increased product yields in comparison to classical heating.^[1] To date, microwave irradiation has been applied successfully to a broad array of reaction types^[1] and has become a standard tool in organic synthesis. Microwave-enhanced cycloadditions have also been reported,^[2] including [3 + 2] cycloadditions of azomethine ylides.^[3]

Recently, we reported the successful synthesis of α -imidazol-1-yl esters through 1,5-electrocyclization of azavinyl azomethine ylides that were ultimately derived from 1,2-diaza-1,3-dienes (henceforth DDs)^[4] and aziridines^[5] or by sequential reaction with α -aminoesters and aldehydes.^[6] In particular, conjugated azavinyl azomethine ylides were generated by heating DD-derived α -aminoester hydrazones in toluene at reflux in the presence of aldehydes, and they were found to undergo an original 1,5-electrocyclization into imidazoles.^[5,6] To follow up our work, we envisioned replacing α -aminoesters with primary aliphatic or aromatic amines, which would allow more general access to simpler

imidazole-4-carboxylates in a one-pot fashion without the need of isolating reaction intermediates. Initial attempts with α -aminohydrazones under the same reactions conditions^[5,6] did provide the desired imidazole-4-carboxylates in very modest yields. Because charged chemical species or intermediates are well known to benefit from microwave irradiation, as in the case of 1,3-dipolar cycloadditions,^[3] we reasoned that our 1,5-electrocyclization of DD-derived azavinyl azomethine ylides could be likewise enhanced by employing microwave heating.

Results and Discussion

DDs **1a** and **1b** were treated with the appropriate amine in acetonitrile at room temperature until complete decoloration of the solution occurred. In the case of DD **1a**, the compound was freshly prepared from the parent chlorohydrazone by preliminary treatment with triethylamine in acetonitrile at room temperature and then used as such without further purification for the following reaction. Subsequent treatment with paraformaldehyde in a sealed vessel under microwave irradiation at 150 °C for 20 min afforded 2-unsubstituted 3*H*-imidazole-4-carboxylates **2a–i** generally in good yields (Table 1), with the exception of **2f** (Table 1, Entries 11 and 12), most presumably due to partial loss of the *tert*-butyl substituent at the nitrogen atom under the reaction conditions employed. Yields with DD **1b** were generally comparable to those with in situ generated **1a**. Aliphatic and aromatic amines (Table 1, Entries 1–14 and 15–18, respectively) performed equally well. When (*R*)- α -phenylethylamine was used (Table 1, Entries 7 and 8), enantiomerically pure imidazole **2d** was recovered (>95% *ee*). Using microwave irradiation, the reaction resulted in higher yields and shorter reaction times than with conventional

[a] Dipartimento di Chimica, Università degli Studi di Modena e Reggio Emilia,
Via Campi 183, 41100 Modena, Italy
Fax: +39-059-373543
E-mail: fabio.prati@unimore.it


[b] Istituto di Chimica Organica, Università degli Studi di Urbino “Carlo Bo”,
Via I Maggetti 24, 61029 Urbino, Italy

[c] Dipartimento di Scienze Chimiche, Università di Trieste,
Via L. Giorgieri 1, 34127 Trieste, Italy

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/ejoc.201000434>.

heating, that is, heating at reflux in toluene. In particular, yields for imidazoles **2a** and **2e** were in the 51–55% range under classical conditions, but rose to 71–77% when microwave heating was employed.

Table 1. One-pot synthesis of 2-unsubstituted 3*H*-imidazole-4-carboxylates **2a–i**.


					
Entry	DD	Amine	Imidazole	2	Yield ^[a] [%]
	1	Y			
1	1a ^[b]	COOEt		2a	78
2	1b	CONH ₂		2b	77
3	1a ^[b]	COOEt		2c	86
4	1b	CONH ₂		2d	62
5	1a ^[b]	COOEt		2e	83
6	1b	CONH ₂		2f	62
7	1a ^[b]	COOEt		2g	75
8	1b	CONH ₂		2h	80
9	1a ^[b]	COOEt		2i	83
10	1b	CONH ₂		2j	71
11	1a ^[b]	COOEt		2k	44
12	1b	CONH ₂		2l	50
13	1a ^[b]	COOEt		2m	75
14	1b	CONH ₂		2n	69
15	1a ^[b]	COOEt		2o	80
16	1b	CONH ₂		2p	31
17	1a ^[b]	COOEt		2q	76
18	1b	CONH ₂		2r	70

[a] Isolated yield (after silica gel chromatography) based on starting material, viz. DD **1b** or the corresponding chlorohydrazone in the case of **1a**. [b] DD **1a** was prepared in situ from the parent chlorohydrazone and used without further purification.

Encouraged by the success with paraformaldehyde, we sought to extend the scope of this one-pot protocol by varying the aldehyde partner. Treatment of DD **1b** and in situ

generated **1a** with benzylamine in acetonitrile at room temperature and subsequent microwave heating in the presence of aliphatic or aromatic aldehydes under the same reaction conditions afforded 2-substituted 3-benzyl imidazole-4-carboxylates **2j–o** in moderate to good yields (Table 2). In the case of butanal and phenylacetaldehyde, yields were excellent with in situ prepared **1a** (Table 2, Entries 1 and 4), but dropped when DD **1b** was used (Table 2, Entries 2 and 5). When butanal was replaced with its dimethyl acetal, imidazole **2j** was still obtained, albeit in lower yield (Table 2, Entry 3). Yields were only moderate with benzaldehyde,

Table 2. One-pot synthesis of 2-substituted 3-benzyl-3*H*-imidazole-4-carboxylates **2j–o**.

					
Entry	DD	Aldehyde	Imidazole	2	Yield ^[a] [%]
	1	Y			
1	1a ^[b]	COOEt		2j	87
2	1b	CONH ₂		2k	37
3	1a ^[b]	COOEt		2l	49
4	1a ^[b]	COOEt		2m	79
5	1b	CONH ₂		2n	48
6	1a ^[b]	COOEt		2o	50
7	1b	CONH ₂		2p	40
8	1a ^[b]	COOEt		2q	74
9	1a ^[b]	COOEt		2r	61
10	1a ^[b]	COOEt		2s	50
11	1b	CONH ₂		2t	44

[a] Isolated yield (after silica gel chromatography) based on starting material, viz. DD **1b** or the corresponding chlorohydrazone in the case of **1a**. [b] DD **1a** was prepared in situ from the parent chlorohydrazone and used without further purification.

either by using **1a** or **1b** as the starting material (Table 2, Entries 10 and 11).

When benzylamine and either paraformaldehyde or butanal were added simultaneously, rather than sequentially, to freshly formed DD **1a**, and the resulting solution was subjected immediately to microwave irradiation, imidazoles **2a** or **2j** were isolated in 71 and 70% yield, respectively. Strictly speaking, therefore, the whole process displays multicomponent character, as all reagents can be mixed at the same time without affecting the reaction outcome and, importantly, with comparable overall yields.

Whilst simple variations of the aldehyde or amine partners allowed access to imidazole 4-carboxylates with dif-


ferent functionalities at C-2 and N-3, respectively, modulation of the substituent at C-5 required the use of an appropriate DD as the starting material. Therefore, additional DDs **1c–f** were allowed to react with benzylamine or allylamine in the presence of paraformaldehyde under the same conditions. 5-Alkyl and 5-arylimidazole-4-carboxylates **2p–w** were isolated in moderate to good yields (Table 3). In particular, yields were higher for imidazoles **2p–s** having an ethyl or a propyl side chain (Table 3, Entries 1–4), whereas DD **1f** gave 5-phenylimidazoles **2v** and **2w** only in moderate yields (Table 3, Entries 7 and 8). Use of benzylamine or allylamine always resulted in comparable yields, except for DD **1e**, which afforded the corresponding 5-methoxycarbonylmethylimidazoles in good yield only for the latter (Table 3, Entries 5 and 6).

A rationale mechanism for the formation of imidazole-4-carboxylates **2a–w** is depicted in Scheme 1. Michael-type 1,4-conjugate addition of DDs **1a–f** (either as an isolated compound or in situ generated from the corresponding chlorohydrazone by treatment with TEA in the case of **1a,c**) with the primary amine gives α -aminohydrazone **A**,^[4e] which in turn condenses with the aldehyde partner to yield iminium ion **B**. Microwave-assisted heating may result in the formation of conjugated azavinyl azomethine ylide^[7,8] **C**, which undergoes 1,5-electrocyclization to 2,3-dehydroimidazole-4-carboxylate **D** and, eventually, aromatization with loss of carbamate or urea, thus affording the desired 3*H*-imidazole-4-carboxylates **2a–w**, by analogy to the formation of DD-derived α -imidazol-1-yl esters we have recently disclosed.^[5,6]

Table 3. One-pot synthesis of 2-unsubstituted 3*H*-imidazole-4-carboxylates **2p–w** using benzylamine or allylamine.

		$\text{RO-C(=O)-CH=CH-N=N-Y} \xrightarrow[\text{iii. MW, 150 } ^\circ\text{C, 20 min}]{\text{i. R}^1\text{NH}_2, \text{MeCN, r.t.}; \text{ii. HCHO}}$			
		1c–f		2p–w	
Entry	DD	Imidazole	2	Yield ^[a]	
	1			[%]	
1	1c ^[b]			2p	69
2	1c ^[b]			2q	78
3	1d			2r	87
4	1d			2s	81
5	1e			2t	59
6	1e			2u	68
7	1f			2v	57
8	1f			2w	62

[a] Isolated yield (after silica gel chromatography) based on starting material, viz. DD **1d–f** or the corresponding chlorohydrazone in the case of **1c**. [b] DD **1c** was prepared in situ from the parent chlorohydrazone and used without further purification.



Scheme 1. Postulated mechanism for the formation of imidazole-4-carboxylates **2a–w** from DDs **1a–f**.

Microwave irradiation has been already employed for the preparation of aryl or alkyl 2,4,5-trisubstituted and 1,2,4,5-tetrasubstituted imidazoles.^[9,10] In particular, a three-component reaction between 1,2-diketones and aldehydes in the presence of ammonium acetate was used for the synthesis of 2,4,5-triaryl- and 2,4,5-trialkylimidazoles,^[9] whereas a four-component variant that also included aliphatic or aromatic amines gave 1,2,4,5-tetrasubstituted imidazoles.^[9b,9c,9i,10] In most of these cases, however, the resulting imidazole products displayed a rather low degree of functionalization that precludes further chemistries. The present method, by contrast, allows the preparation of functionalized imidazoles whose substituents are amenable to subsequent manipulations, especially in the framework of target-driven multistep syntheses.

Conclusions

We have reported a significant extension of the 1,5-electrocyclization of conjugated azavinyl azomethine ylides^[5,6] to substituted imidazole-4-carboxylates by one-pot sequential reaction between DDs and primary amines, followed by microwave-assisted heating in the presence of aldehydes. The method is efficient and straightforward and does not require isolation of intermediates. Moreover, appropriate choice of the amine, aldehyde, and DD partners makes possible the modulation of substituents at the N-3, C-2, and C-5 atoms of the final product, respectively. Noteworthy is that the reaction can be also performed in a multicomponent fashion by simply mixing the three partners at room temperature and subjecting them to microwave irradiation. Such a one-pot multicomponent approach is most flexible and useful for the synthesis of functionalized imidazole-4-carboxylates starting from readily available materials such as aliphatic or aromatic primary amines and aldehydes and nicely adds to the variety of available methods to access the biologically important and pharmaceutically relevant imidazole skeleton.^[11]

Experimental Section

General Methods: Microwave-assisted reactions were performed in sealed glass vials by using a temperature- and pressure-controlled single-mode microwave reactor (CEM, Discover LabMate) equipped with a 300 W power source. Temperature and pressure were set at 150 °C and 150 psi, respectively, power source at 150 W. Such values were reached within 5 min and were maintained for further 20 min by IR sensor thermal control and pressure feedback control. Commercial-grade acetonitrile was used without further purification as reaction solvent. 1,2-Diaza-1,3-dienes (DDs) **1a,b** were synthesized as already described and occur both as a mixture of *E/Z* isomers.^[12] Whereas DD **1b** is a shelf-stable red crystalline compound,^[12b] DD **1a**^[12a] is a somewhat unstable red liquid that tends to decompose upon prolonged storage. Therefore, **1a** was always generated *in situ* by treatment of the parent chlorohydrazone with triethylamine in acetonitrile at room temperature, and the resulting red solution was used as such for the subsequent chemistry without further purification. DDs **1c–f** were synthesized according

to the procedure described below. Amines and aldehydes were purchased from Sigma–Aldrich and used as received, except for thiophen-2-yl-acetaldehyde, phenoxyacetaldehyde, and 2-phenoxypropanal (used for the synthesis of imidazole-4-carboxylates **2l**, **2m** and **2n**, respectively), which were prepared by reduction of the parent methyl ester with DIBALH by analogy to a literature procedure^[13] (see the Supporting Information). Chromatographic purification of compounds was performed on silica gel (60–200 µm) by using the appropriate eluant as specified; commercial-grade light petroleum ether/ethyl acetate mixtures were used for such purpose. Preloaded (0.25 mm) glass supported silica gel plates (Kieselgel 60, Merck) were used for TLC analysis, and compounds were visualized by exposure to UV light and by dipping the plates in 1% Ce(SO₄)·4H₂O, 2.5% (NH₄)₆Mo₇O₂₄·4H₂O in 10% sulfuric acid followed by heating on a hot plate. Melting points were determined in open capillary tubes. ¹H and ¹³C NMR spectra were recorded in CDCl₃ solution at 25 °C with Bruker 200 or 400 MHz instruments. Multiplicity is given as s = singlet, d = doublet, t = triplet, q = quartet, sext. = sextet, m = multiplet, and br. = broad signal, and chemical shifts (δ) are reported in ppm downfield from tetramethylsilane as internal standard. Coupling constants (³J_{H,H}) are given in Hz. COSY, HSQC, and HMBC experiments were performed to aid in the assignment of ¹H and ¹³C resonances. Mass spectra were recorded in the EI mode (70 eV). For elemental analyses, a Carlo Erba Elemental Analyzer (model 1110) was used. The enantiomeric excess (*ee*) of imidazole **2d** was determined by chiral HPLC analysis (Jasco PU-980) by using a Lux Cellulose-I column (5 µm; 250 × 4.6 mm; Phenomenex, Torrance, CA, US). The mobile phase consisted of *n*-hexane/2-propanol (9:1) under isocratic elution at a flow rate of 0.7 mL min⁻¹ at 20 °C; samples were dissolved in *n*-hexane/2-propanol (1:1) and the injection volume was 20 µL. Detection was performed at 254 nm by using a variable wavelength detector (Jasco UV-1575). Accuracy was within ±5%.

Procedure for the Synthesis of DDs 1c–e: Commercially available methyl 2-chloro-3-oxopentanoate (5 mmol) or freshly prepared (see below) ethyl 2-chloro-3-oxohexanoate (5 mmol), or dimethyl 2-chloro-3-oxopentanedioate (5 mmol) was added to a magnetically stirred solution of semicarbazide hydrochloride (5 mmol, pretreated with an equimolecular amount of sodium acetate) or methyl carbazate (5 mmol) in tetrahydrofuran (50 mL, **1c**) or methanol (50 mL, **1d,e**). The reaction was magnetically stirred at room temperature until the disappearance of the reagents (TLC). The reaction solvent was evaporated under reduced pressure, the crude α-chlorohydrazone was dissolved in ethyl acetate and washed with an aqueous saturated solution of sodium carbonate (2 × 50 mL) and with an aqueous solution of sodium hydroxide (1%, 1 × 50 mL, only for **1c,d**). Ethyl acetate was removed under reduced pressure, and the crude residue was purified by chromatography on silica gel column to afford DDs **1c–e**.

Ethyl 2-Chloro-3-oxohexanoate or Dimethyl 2-Chloro-3-oxopentanedioate: As required for the synthesis of DDs **1d,e**, the compound was prepared from the parent ethyl 3-oxohexanoate (5 mmol) or dimethyl 3-oxopentanedioate (5 mmol) by chlorination with sulfuric acid (SO₂Cl₂, 5.5 mmol). The reaction was performed in dichloromethane (10 mL) at room temperature under magnetic stirring for 15–30 min (monitored by TLC and/or ¹H NMR spectroscopy). Thereafter, the reaction mixture was washed with brine (5 × 30 mL), dried (MgSO₄), filtered, and concentrated under reduced pressure to afford the desired α-chlorohydrazone as a colorless oil.

Procedure for the Synthesis of DD 1f: Ethyl 3-oxo-3-phenylpropanoate (5 mmol) was treated with *tert*-butyl carbazate (5 mmol,

1 equiv.) and a catalytic amount of *p*-toluenesulfonic acid in a minimum amount of tetrahydrofuran (5 mL). The reaction mixture was allowed to react at room temperature for 48 h. The desired hydrazone separated as a white solid, which was recovered by filtration and washed with light petroleum ether. The hydrazone was then dissolved in dichloromethane and sulfonyl chloride (1.1 equiv.) was added at room temperature, and the resulting solution was allowed to react for 30 min under magnetic stirring. Thereafter, the reaction mixture was washed with brine (5 × 30 mL), and the organic layer was dried with magnesium sulfate, filtered, and concentrated under reduced pressure to give α -chlorohydrazone as a pale-yellow oil. Finally, addition of *N,N*-diisopropylethylamine (1.0 equiv.) to a magnetically stirred solution of the α -chlorohydrazone in a minimum amount of dichloromethane at room temperature for 5 min assisted to the 1,2-diaza-1,3-diene formation. The resulting red-orange solution was directly purified by column chromatography (cyclohexane/ethyl acetate, 90:10) to give DD **1f** as a somewhat unstable red liquid that tends to decompose upon storage.

4-Methoxycarbonyl-3-ethyl-1-methoxycarbonyl-1,2-diaza-1,3-diene (1c): DD **1c** was isolated (540 mg, 54%) by column chromatography (cyclohexane/ethyl acetate, 90:10). ¹H NMR (400 MHz, CDCl₃): δ = 6.84 (s, 1 H, CH), 4.03 (s, 3 H, OCH₃), 3.83 (s, 3 H, OCH₃), 2.83 (q, *J* = 7.6 Hz, 2 H, CH₂CH₃), 1.01 (t, *J* = 7.6 Hz, 3 H, CH₂CH₃) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.4 (CO₂CH₃), 165.7 (NCO₂CH₃), 162.7 (C-3), 131.1 (C-4), 54.9 (OCH₃), 52.0 (OCH₃), 17.7 (CH₂), 12.2 (CH₃) ppm. MS (EI): *m/z* (%) = 200 (1) [M]⁺, 167 (2), 149 (5), 125 (10), 111 (22), 97 (38), 83 (39), 69 (60), 57 (100). C₈H₁₂N₂O₄ (200.08): calcd. C 48.00, H 6.04, N 13.99; found C 47.81, H 6.31, N 14.23.

4-Ethoxycarbonyl-3-propyl-1-aminocarbonyl-1,2-diaza-1,3-diene (1d): DD **1d** was isolated (499 mg, 47%) by column chromatography (cyclohexane/ethyl acetate, 65:35). ¹H NMR (400 MHz, CDCl₃): δ = 6.87 (s, 1 H, CH), 6.23 and 6.02 (br., 2 H, NH₂), 4.29 (q, *J* = 7.2 Hz, 2 H, CH₃CH₂O), 2.85 (t, *J* = 7.6 Hz, 2 H, CH₂CH₂CH₃), 1.43 (sext., *J* = 7.6 Hz, 2 H, CH₂CH₂CH₃), 1.37 (t, *J* = 7.6 Hz, 3 H, CH₂CH₂CH₃), 0.91 (t, *J* = 7.2 Hz, 3 H, CH₃CH₂O) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 166.4 (CO₂CH₂CH₃), 165.4 (NCO₂NH₂), 161.1 (C-3), 132.1 (C-4), 61.1 (OCH₂CH₃), 26.3 (CH₂CH₂CH₃), 21.3 (CH₂CH₂CH₃), 14.1 (2 CH₃) ppm. MS (EI): *m/z* (%) = 170 (3), 141 (27), 125 (72), 113 (50), 99 (60), 85 (24), 67 (66), 55 (100). C₉H₁₅N₃O₃ (213.11): calcd. C 50.69, H 7.09, N 19.71; found C 50.47, H 7.33, N 19.63.

4-Methoxycarbonyl-3-(2-methoxy-2-oxoethyl)-1-aminocarbonyl-1,2-diaza-1,3-diene (1e): DD **1e** was isolated (492 mg, 43%) by column chromatography (cyclohexane/ethyl acetate, 40:60). ¹H NMR (400 MHz, CDCl₃): δ = 7.21 (s, 1 H, CH), 6.28 and 6.02 (br., 2 H, NH₂), 4.03 (s, 3 H, CH₃O), 3.86 (s, 3 H, CH₃O), 3.66 (s, 2 H, CH₂CO₂Me) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1 (CH₂CO₂CH₃), 165.5 (CO₂CH₃), 161.2 (NCO₂NH₂), 158.9 (C-3), 135.2 (C-4), 52.3 (2 OCH₃), 30.4 (CH₂) ppm. MS (EI): *m/z* (%) = 155 (68), 126 (56), 98 (100), 85 (70), 68 (58), 59 (100). C₈H₁₁N₃O₅ (229.07): calcd. C 41.92, H 4.84, N 18.33; found C 42.07, H 4.67, N 18.09.

4-Ethoxycarbonyl-3-phenyl-1-tert-butoxycarbonyl-1,2-diaza-1,3-diene (1f): DD **1f** was isolated (851 mg, 56%) by column chromatography (cyclohexane/ethyl acetate, 90:10). ¹H NMR (400 MHz, CDCl₃): δ = 7.42–7.37 (m, 3 H, CHAr), 7.24–7.20 (m, 2 H, CHAr), 6.92 (s, 1 H, CH), 4.11 (q, *J* = 7.2 Hz, 2 H, OCH₂CH₃), 1.59 [s, 9 H, (CH₃)₃], 1.12 (t, *J* = 7.2 Hz, 3 H, OCH₂CH₃) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 164.8 (CO₂CH₂CH₃), 163.0 (NCO₂tBu), 161.2 (C-3), 134.2 (CHAr), 130.4 (C-4), 129.4 (CHAr), 129.0 (CHAr), 127.8 (CHAr), 85.6

[C(CH₃)₃], 60.9 (OCH₂CH₃), 27.7 [(CH₃)₃], 13.8 (CH₃) ppm. MS (EI): *m/z* (%) = 176 (27), 21(16), 131 (100), 103 (64), 77 (30). C₁₆H₂₀N₂O₄ (304.14): calcd. C 63.14, H 6.62, N 9.20; found C 63.01, H 6.85, N 9.04.

Typical Procedure for the Synthesis of Imidazole-4-carboxylates from DDs 1a,c (Method A): Ethyl 2-chloro-3-(ethoxycarbonylhydrazono)butanoate^[12] (0.6 mmol) or methyl 2-chloro-3-(methoxycarbonylhydrazono)pentanoate (0.6 mmol) was dissolved in acetonitrile (2 mL) in a microwave glass vial and treated with TEA (84 μ L, 0.6 mmol) at room temperature under magnetic stirring to give a red solution. The primary amine (0.63 mmol) was added, and the resulting solution was stirred until complete decoloration of the solution, whereupon the aldehyde (1.2 mmol) was added. The vessel containing the pale-yellow mixture was then sealed and heated under microwave irradiation at 150 °C for 20 min. After removal of the solvent in vacuo, purification by column chromatography afforded the desired imidazole.

Typical Procedure for the Synthesis of Imidazole-4-carboxylates from DDs 1b,d–f (Method B): A solution of DD **1b**,^[12b] **d–f** (0.54 mmol) in acetonitrile (2 mL) in a microwave glass vial equipped with a stir bar was treated with the amine (0.57 mmol) at room temperature until complete decoloration of the solution. The aldehyde (1.08 mmol) was added, and the vessel with the resulting light-yellow mixture was sealed and heated under microwave irradiation at 150 °C for 20 min. The solvent was evaporated under reduced pressure, and the crude residue was purified by column chromatography to yield the desired imidazole-4-carboxylate.

Ethyl 3-Benzyl-5-methyl-3H-imidazole-4-carboxylate (2a): Imidazole **2a** was isolated (method A: 114 mg, 78%; method B: 101 mg, 77%) by column chromatography (light petroleum ether/ethyl acetate, 50:50) as a pale-yellow solid, m.p. 54–56 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.72 (s, 1 H, 2-H), 7.33 (m, 3 H, 3'-H, 4'-H, 5'-H), 7.18 (m, 2 H, 2'-H, 6'-H), 5.52 (s, 2 H, CH₂Ph), 4.30 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 2.56 (s, 3 H, CH₃C), 1.34 (t, *J* = 7.1 Hz, 3 H, CH₃CH₂O) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 160.7 (C=O), 147.6 (C-5), 140.0 (C-2), 136.3 (C-1'), 128.9 (C-3', C-5'), 128.1 (C-4'), 127.2 (C-2', C-6'), 118.8 (C-4), 60.5 (CH₃CH₂O), 50.9 (CH₂Ph), 15.6 (CH₃), 14.2 (CH₃CH₂O) ppm. MS (EI): *m/z* (%) = 244 (14) [M]⁺, 198 (12), 109 (8), 91 (100), 65 (10). C₁₄H₁₆N₂O₂ (244.12): calcd. C 68.83, H 6.60, N 11.47; found C 70.12, H 6.92, N 11.79.

Ethyl 3-Allyl-5-methyl-3H-imidazole-4-carboxylate (2b): Imidazole **2b** was isolated (method A: 100 mg, 86%; method B: 65 mg, 62%) by column chromatography (light petroleum ether/ethyl acetate, 50:50) as a yellow liquid. ¹H NMR (400 MHz, CDCl₃): δ = 7.48 (s, 1 H, 2-H), 5.93 (ddt, *J* = 17.1, 10.3, 5.5 Hz, 1 H, CH₂CH), 5.14 (ddd, *J* = 10.3, 2.6, 1.2 Hz, 1 H, *H*_{cis}), 5.01 (ddd, *J* = 17.1, 2.6, 1.6 Hz, 1 H, *H*_{trans}), 4.82 (dt, *J* = 5.5, 1.4 Hz, 2 H, NCH₂), 4.26 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 2.44 (s, 3 H, CH₃C), 1.31 (t, *J* = 7.1 Hz, 3 H, CH₃CH₂O) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 160.9 (C=O), 148.0 (C-5), 139.9 (C-2), 133.3 (NCH₂CH), 118.5 (C-4), 117.7 (CHCH₂), 60.3 (CH₃CH₂O), 49.4 (CH₂N), 15.8 (CH₃C), 14.3 (CH₃CH₂O) ppm. MS (EI): *m/z* (%) = 194 (68) [M]⁺, 165 (58), 149 (67), 121 (78), 109 (33), 94 (25), 80 (21), 67 (24), 54 (22), 41 (100). C₁₀H₁₄N₂O₂ (194.11): calcd. C 61.84, H 7.27, N 14.42; found C 62.09, H 7.07, N 14.71.

Ethyl 5-Methyl-3-prop-2-ynyl-3H-imidazole-4-carboxylate (2c): Imidazole **2c** was isolated (method A: 96 mg, 83%; method B: 64 mg, 62%) by column chromatography (light petroleum ether/ethyl acetate, 70:30) as a pale-yellow solid, m.p. 56–58 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.51 (s, 1 H, 2-H), 4.82 (d, *J* = 2.5 Hz, 2 H, NCH₂), 4.10 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 2.27 (t, *J* = 2.5 Hz, 1

H, $C\equiv CH$), 2.24 (s, 3 H, CH_3C), 1.14 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O) ppm. ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 161.00$ (C=O), 148.6 (C-5), 139.6 (C-2), 118.4 (C-4), 76.8 ($C\equiv CH$), 74.9 ($C\equiv CH$), 60.5 (CH_3CH_2O), 37.1 (NCH_2), 15.8 (CH_3C), 14.3 (CH_3CH_2O) ppm. MS (EI): m/z (%) = 192 (19) $[M]^+$, 163 (100), 147 (28), 136 (20), 119 (11), 109 (29), 92 (13), 65 (17), 52 (16), 39 (55). $C_{10}H_{12}N_2O_2$ (192.09): calcd. C 62.49, H 6.29, N 14.57; found C 62.74, H 6.44, N 14.80.

Ethyl (3*R*)-5-Methyl-3-(1-phenylethyl)-3*H*-imidazole-4-carboxylate (2d): Imidazole **2d** was isolated (method A: 116 mg, 75%; method B: 112 mg, 80%) by column chromatography (light petroleum ether/ethyl acetate, 50:50) as a pale-yellow liquid, $[a]_D^{25} = +48.3$ ($c = 1.5$, CH_2Cl_2), 98% ee (by chiral HPLC analysis). 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.66$ (s, 1 H, 2-H), 7.25 (m, 3 H, 3'-H, 4'-H, 5'-H), 7.10 (d, $J = 7.1$ Hz, 2 H, 2'-H, 6'-H), 6.27 (q, $J = 7.1$ Hz, 1 H, NCH), 4.22 (q, $J = 7.1$ Hz, 1 H, CH_3CH), 4.20 (q, $J = 7.1$ Hz, 1 H, CH_3CH_2O), 2.45 (s, 3 H, CH_3C), 1.78 (d, $J = 7.1$ Hz, 3 H, CH_3CH), 1.26 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O) ppm. ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 160.9$ (C=O), 147.8 (C-5), 141.3 (C-1'), 137.7 (C-2), 128.8 (C-3', C-5'), 127.9 (C-4'), 126.2 (C-2', C-6'), 118.8 (C-4), 60.4 (CH_3CH_2O), 55.9 (NCH), 22.3 (NCH CH_3), 15.8 (CH_3C), 14.2 (CH_3CH_2O) ppm. MS (EI): m/z (%) = 258 (5) $[M]^+$, 154 (8), 105 (100), 77 (15). $C_{15}H_{18}N_2O_2$ (258.14): calcd. C 69.74, H 7.02, N 10.84; found C 70.02, H 7.30, N 11.04.

Ethyl 3-sec-Butyl-5-methyl-3*H*-imidazole-4-carboxylate (2e): Imidazole **2e** was isolated (method A: 105 mg, 83%; method B: 81 mg, 71%) by column chromatography (light petroleum ether/ethyl acetate, 50:50) as a pale-yellow liquid. 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.67$ (s, 1 H, 2-H), 5.05 (m, 1 H, CH), 4.30 (q, $J = 7.1$ Hz, 2 H, CH_3CH_2O), 2.47 (s, 3 H, CH_3C), 1.77 (m, 2 H, CH_3CH_2CH), 1.43 (d, $J = 6.8$ Hz, 3 H, CH_3CH), 1.35 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O), 0.85 (t, $J = 7.4$ Hz, 3 H, CH_3CH_2CH) ppm. ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 161.2$ (C=O), 147.4 (C-5), 136.9 (C-2), 118.6 (C-4), 60.3 (CH_3CH_2O), 54.0 (CH_3CH_2CH), 30.6 (CH_3CH_2CH), 21.2 (CH_3CH), 15.9 (CH_3C), 14.3 (CH_3CH_2O), 10.3 (CH_3CH_2CH) ppm. MS (EI): m/z (%) = 210 (39) $[M]^+$, 181 (8), 165 (14), 154 (17), 137 (25), 125 (95), 109 (100), 82 (17), 54 (17), 41 (27). $C_{11}H_{18}N_2O_2$ (210.14): calcd. C 62.83, H 8.63, N 13.32; found C 63.18, H 8.95, N 13.56.

Ethyl 3-tert-Butyl-5-methyl-3*H*-imidazole-4-carboxylate (2f): Imidazole **2f** was isolated (method A: 56 mg, 44%; method B: 57 mg, 50%) by column chromatography (light petroleum ether/ethyl acetate, 50:50) as a pale-yellow liquid. 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.73$ (s, 1 H, 2-H), 4.30 (q, $J = 7.1$ Hz, 2 H, CH_3CH_2O), 2.44 (s, 3 H, CH_3C), 1.68 [s, 9 H, (CH_3) $_3C$], 1.36 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O) ppm. ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 161.6$ (C=O), 149.1 (C-5), 137.4 (C-2), 120.0 (C-4), 60.6 (CH_3CH_2O), 58.7 [(CH_3) $_3C$], 30.1 [(CH_3) $_3C$], 16.5 (CH_3C), 14.3 (CH_3CH_2O) ppm. MS (EI): m/z (%) = 210 (10) $[M]^+$, 154 (89), 125 (100), 109 (81), 82 (22), 57 (55), 41 (47). $C_{11}H_{18}N_2O_2$ (210.14): calcd. C 62.83, H 8.63, N 13.32; found C 63.04, H 8.88, N 13.65.

Ethyl 3-[2-(4-Methoxyphenyl)-2-oxoethyl]-5-methyl-3*H*-imidazole-4-carboxylate (2g): Imidazole **2g** was isolated (method A: 136 mg, 75%; method B: 113 mg, 69%) by column chromatography (light petroleum ether/ethyl acetate, 50:50) as a pale-yellow solid, m.p. 116–118 °C. 1H NMR (400 MHz, $CDCl_3$): $\delta = 8.11$ (s, 1 H, 2-H), 7.97 (d, $J = 8.9$ Hz, 3 H, 3'-H, 4'-H, 5'-H), 6.98 (d, $J = 8.9$ Hz, 2 H, 2'-H, 6'-H), 5.79 (s, 2 H, CH_2CO), 4.22 (q, $J = 7.1$ Hz, 2 H, CH_3CH_2O), 3.88 (s, 3 H, CH_3O), 2.57 (s, 3 H, CH_3C), 1.25 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O) ppm. ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 189.9$ (CO CH_2), 164.4 (C-4'), 160.6 (C=O), 145.4 (C-5), 140.4 (C-2), 130.4 (C-3', C-5'), 127.3 (C-1'), 119.3 (C-4), 114.2 (C-2', C-6'),

60.8 (CH_3CH_2O), 55.6 (CH_3O), 53.3 (CH_2CO), 14.9 (CH_3C), 14.2 (CH_3CH_2O) ppm. MS (EI): m/z (%) = 302 (3) $[M]^+$, 135 (100), 92 (7), 77 (11). $C_{16}H_{18}N_2O_4$ (302.13): calcd. C 63.56, H 6.00, N 9.27; found C 63.66, H 6.25, N 9.50.

Ethyl 5-Methyl-3-phenyl-3*H*-imidazole-4-carboxylate (2h): Imidazole **2h** was isolated (method A: 111 mg, 80%; method B: 39 mg, 31%) by column chromatography (light petroleum ether/ethyl acetate, 50:50) as a pale-yellow solid, m.p. 47–49 °C. 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.63$ (s, 1 H, 2-H), 7.44 (m, 3 H, 3'-H, 4'-H, 5'-H), 7.27 (m, 2 H, 2'-H, 6'-H), 4.15 (q, $J = 7.1$ Hz, 2 H, CH_3CH_2O), 2.58 (s, 3 H, CH_3C), 1.13 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O) ppm. ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 160.1$ (C=O), 147.7 (C-5), 140.0 (C-2), 137.1 (C-1'), 128.89 (C-3', C-5'), 128.86 (C-4'), 126.3 (C-2', C-6'), 120.3 (C-4), 60.4 (CH_3CH_2O), 15.2 (CH_3C), 14.0 (CH_3CH_2O) ppm. MS (EI): m/z (%) = 230 (59) $[M]^+$, 201 (63), 185 (49), 158 (29), 130 (30), 104 (18), 77 (100), 51 (45). $C_{13}H_{14}N_2O_2$ (230.11): calcd. C 67.81, H 6.13, N 12.17; found C 68.11, H 6.30, N 12.44.

Ethyl 3-(4-Dimethylaminophenyl)-5-methyl-3*H*-imidazole-4-carboxylate (2i): Imidazole **2i** was isolated (method A: 125 mg, 76%; method B: 103 mg, 70%) by column chromatography (petroleum ether/ethyl acetate, 50:50) as a pale-brown solid, m.p. 96–98 °C. 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.66$ (s, 1 H, 2-H), 7.11 (d, $J = 9.0$ Hz, 2 H, 3'-H, 5'-H), 6.71 (d, $J = 9.0$ Hz, 2 H, 2'-H, 6'-H), 4.19 (q, $J = 7.1$ Hz, 2 H, CH_3CH_2O), 3.00 [s, 6 H, N(CH_3) $_2$], 2.59 (s, 3 H, CH_3C), 1.20 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O) ppm. ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 160.0$ (C=O), 150.7 (C-4'), 146.0 (C-5), 139.7 (C-2), 126.9 (C-2', C-6'), 125.4 (C-1'), 120.7 (C-4), 111.7 (C-3', C-5'), 60.5 (CH_3CH_2O), 40.5 [N(CH_3) $_2$], 15.0 (CH_3C), 14.1 (CH_3CH_2O) ppm. MS (EI): m/z (%) = 273 (100) $[M]^+$, 227 (15), 200 (29), 173 (17), 159 (38), 147 (70), 132 (31), 121 (40), 113 (17), 105 (21), 86 (19), 77 (28), 42 (19). $C_{15}H_{19}N_3O_2$ (273.15): calcd. C 65.91, H 7.01, N 15.37; found C 66.33, H 7.45, N 15.60.

Ethyl 3-Benzyl-5-methyl-2-propyl-3*H*-imidazole-4-carboxylate (2j): Imidazole **2j** was isolated (method A: 149 mg, 87% using butanal, 84 mg, 49% using 1,1-dimethoxybutane; method B: 57 mg, 37%) by column chromatography (light petroleum ether/ethyl acetate, 70:30) as a yellow oil. 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.05$ (m, 3 H, 3'-H, 4'-H, 5'-H), 6.73 (d, $J = 7.2$ Hz, 2 H, 2'-H, 6'-H), 5.29 (s, 2 H, NCH $_2$ Ph), 3.99 (q, $J = 7.1$ Hz, 2 H, CH_3CH_2O), 2.37 (t, $J = 7.9$ Hz, 2 H, $CH_3CH_2CH_2$), 2.28 (s, 3 H, CH_3C), 1.46 (m, $J = 7.7$ Hz, 2 H, $CH_3CH_2CH_2$), 1.04 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O), 0.69 (t, $J = 7.3$ Hz, 3 H, $CH_3CH_2CH_2$) ppm. ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 161.1$ (C=O), 152.4 (C-2), 147.1 (C-5), 137.2 (C-1'), 128.7 (C-3', C-5'), 127.4 (C-4'), 125.8 (C-2', C-6'), 118.4 (C-4), 60.1 (CH_3CH_2O), 48.1 (NCH $_2$), 29.0 ($CH_3CH_2CH_2$), 21.3 ($CH_3CH_2CH_2$), 15.8 (CH_3C), 14.2 (CH_3CH_2O), 13.9 ($CH_3CH_2CH_2$) ppm. MS (EI): m/z (%) = 286 (9) $[M]^+$, 257 (13), 167 (11), 91 (100), 65 (12). $C_{17}H_{22}N_2O_2$ (286.17): calcd. C 71.30, H 7.74, N 9.78; found C 71.67, H 7.90, N 10.02.

Ethyl 2,3-Dibenzyl-5-methyl-3*H*-imidazole-4-carboxylate (2k): Imidazole **2k** was isolated (method A: 159 mg, 79%; method B: 86 mg, 48%) by column chromatography (light petroleum ether/ethyl acetate, 70:30) as a yellow oil. 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.30$ –7.19 (m, 6 H, 3'-H, 4'-H, 5'-H, 3''-H, 4''-H, 5''-H), 7.13 (m, 2 H, 2'-H, 6'-H), 6.89 (m, 2 H, 2''-H, 6''-H), 5.41 (s, 2 H, NCH $_2$ Ph), 4.23 (q, $J = 7.1$ Hz, 2 H, CH_3CH_2O), 4.06 (s, 2 H, CCH $_2$ Ph), 2.57 (s, 3 H, CH_3C), 1.27 (t, $J = 7.1$ Hz, 3 H, CH_3CH_2O) ppm. ^{13}C NMR (400 MHz, $CDCl_3$): $\delta = 160.8$ (C=O), 150.2 (C-2), 146.3 (C-5), 136.6 (C-1''), 135.7 (C-1'), 128.9 (C-3', C-5'), 128.8 (C-3'', C-5''), 128.4 (C-2', C-6'), 127.5 (C-4''), 127.1 (C-4'), 125.8 (C-2'', C-6''), 119.2 (C-4), 60.4 (CH_3CH_2O), 48.4 (NCH $_2$ Ph), 33.4

(CCH₂Ph), 15.6 (CH₃C), 14.2 (CH₃CH₂O) ppm. MS (EI): *m/z* (%) = 334 (14) [M]⁺, 243 (12), 215 (9), 167 (13), 91 (100), 65 (13). C₂₁H₂₂N₂O₂ (334.17): calcd. C 75.42, H 6.63, N 8.38; found C 75.60, H 6.77, N 8.61.

Ethyl 3-Benzyl-5-methyl-2-thiophen-2-ylmethyl-3H-imidazole-4-carboxylate (2l): Imidazole **2l** was isolated (method A: 102 mg, 50%; method B: 74 mg, 40%) by column chromatography (light petroleum ether/ethyl acetate, 70:30) as a pale-yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 7.31–7.21 (m, 3 H, 3'-H, 4'-H, 5'-H), 7.14 (dd, *J* = 5.1, 1.1 Hz, 1 H, 5'-H), 6.93 (d, *J* = 7.0 Hz, 2 H, 2''-H, 6''-H), 6.88 (dd, *J* = 5.1, 3.6 Hz, 1 H, 4'-H), 6.75 (dd, *J* = 3.6, 1.1 Hz, 1 H, 3'-H), 5.49 (s, 2 H, NCH₂Ph), 4.23 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 4.17 (s, 2 H, CCH₂-C-2'), 2.54 (s, 3 H, CH₃C), 1.28 (t, *J* = 7.1 Hz, 3 H, CH₃CH₂O) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 161.1 (C=O), 149.6 (C-2), 147.2 (C-5), 138.2 (C-2'), 136.8 (C-1'), 128.8 (C-3'', C-5''), 127.4 (C-4'), 127.0 (C-4''), 125.9 (C-3'), 125.8 (C-2'', C-6''), 124.7 (C-5'), 119.2 (C-4), 60.2 (CH₃CH₂O), 48.4 (NCH₂), 28.4 (CCH₂-C-2'), 16.0 (CH₃C), 14.2 (CH₃CH₂O) ppm. MS (EI): *m/z* (%) = 340 (13) [M]⁺, 249 (11), 173 (15), 91 (100), 65 (13). C₁₉H₂₀N₂O₂S (340.12): calcd. C 67.03, H 5.92, N 8.23, S 9.42; found C 66.72, H 6.25, N 8.39, S 9.18.

Ethyl 3-Benzyl-5-methyl-2-phenoxymethyl-3H-imidazole-4-carboxylate (2m): Imidazole **2m** was isolated (method A: 156 mg, 74%) by column chromatography (light petroleum ether/ethyl acetate, 70:30) as a brown solid, m.p. 51–53 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.28–7.22 (m, 5 H, 3'-H, 5'-H, 3''-H, 4''-H, 5''-H), 7.01–6.93 (m, 3 H, 4'-H, 2''-H, 6''-H), 6.90 (d, *J* = 8.0 Hz, 2 H, 2'-H, 6'-H), 5.69 (s, 1 H, NCH₂Ph), 5.05 (s, 2 H, CCH₂O), 4.25 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 2.54 (s, 3 H, CH₃C), 1.27 (t, *J* = 7.1 Hz, 3 H, CH₃CH₂O) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 160.9 (C=O), 157.8 (C-1'), 147.0 (C-2), 146.6 (C-5), 137.0 (C-1''), 129.6 (C-3', C-5'), 128.7 (C-3'', C-5''), 127.4 (C-4'), 126.1 (C-2'', C-6''), 121.6 (C-4'), 120.3 (C-4), 114.8 (C-2', C-6'), 62.5 (CCH₂O), 60.4 (CH₃CH₂O), 48.8 (NCH₂Ph), 15.9 (CH₃C), 14.2 (CH₃CH₂O) ppm. MS (EI): *m/z* (%) = 305 (1) [M – EtO]⁺, 257 (18), 211 (19), 183 (2), 115 (3), 91 (100), 77 (3), 65 (12), 39 (4). C₂₁H₂₂N₂O₃ (350.16): calcd. C 71.98, H 6.33, N 7.99; found C 72.30, H 6.55, N 8.28.

Ethyl 3-Benzyl-5-methyl-2-(1-phenoxyethyl)-3H-imidazole-4-carboxylate (2n): Imidazole **2n** was isolated (Method A: 133 mg, 61%) by column chromatography (light petroleum ether/ethyl acetate, 70:30) as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 7.25–7.16 (m, 5 H, 3'-H, 5'-H, 3''-H, 4''-H, 5''-H), 6.95–6.85 (m, 3 H, 4'-H, 2''-H, 6''-H), 6.81 (d, *J* = 8.0 Hz, 2 H, 2'-H, 6'-H), 5.78 (d, *J* = 16.3 Hz, 1 H, CH₂Ph), 5.58 (d, *J* = 16.3 Hz, 1 H, CH₂Ph), 5.50 (q, *J* = 6.6 Hz, 1 H, CH₃CH₂O), 4.19 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 2.55 (s, 3 H, CH₃C), 1.65 (d, *J* = 6.6 Hz, 3 H, CH₃CH), 1.23 (t, *J* = 7.1 Hz, 3 H, CH₃CH₂O) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 160.8 (C=O), 157.1 (C-1'), 150.3 (C-2), 146.9 (C-5), 137.4 (C-1''), 129.6 (C-3', C-5'), 128.6 (C-3'', C-5''), 127.2 (C-4'), 125.7 (C-2'', C-6''), 121.6 (C-4'), 120.0 (C-4), 115.6 (C-2', C-6'), 69.7 (CH₃CH), 60.3 (CH₃CH₂O), 48.6 (CH₂Ph), 19.3 (CH₃CH), 15.9 (CH₃C), 14.2 (CH₃CH₂O) ppm. MS (EI): *m/z* (%) = 364 (1) [M]⁺, 319 (1), 271 (26), 225 (5), 135 (4), 91 (100), 65 (11), 39 (5). C₂₂H₂₄N₂O₃ (364.18): calcd. C 72.50, H 6.64, N 7.69; found C 72.33, H 6.90, N 7.88.

Ethyl 3-Benzyl-5-methyl-2-phenyl-3H-imidazole-4-carboxylate (2o): Imidazole **2o** was isolated (method A: 96 mg, 50%; method B: 76 mg, 44%) by column chromatography (light petroleum ether/ethyl acetate, 70:30) as a pale-yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 7.52 (m, 2 H, 2'-H, 6'-H), 7.42–7.33 (m, 3 H, 3'-H, 4'-H, 5'-H), 7.31–7.20 (m, 3 H, 3''-H, 4''-H, 5''-H), 6.95 (d, *J* =

7.2 Hz, 2 H, 2''-H, 6''-H), 5.58 (s, 2 H, NCH₂Ph), 4.22 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 2.61 (s, 3 H, CH₃C), 1.24 (t, *J* = 7.1 Hz, 3 H, CH₃CH₂O) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 161.1 (C=O), 151.5 (C-2), 148.2 (C-5), 138.1 (C-1''), 134.0 (C-1'), 129.9 (C-4'), 129.4 (C-2', C-6'), 128.82 (C-3', C-5'), 128.78 (C-3'', C-5''), 127.4 (C-4''), 125.8 (C-2'', C-6''), 119.7 (C-4), 60.4 (CH₃CH₂O), 49.8 (NCH₂), 16.0 (CH₃C), 14.3 (CH₃CH₂O) ppm. MS (EI): *m/z* (%) = 320 (12) [M]⁺, 274 (3), 115 (4), 104 (6), 91 (100), 65 (8). C₂₀H₂₀N₂O₂ (320.15): calcd. C 74.98, H 6.29, N 8.74; found C 75.18, H 6.33, N 8.92.

Methyl 3-Benzyl-5-ethyl-3H-imidazole-4-carboxylate (2p): Imidazole **2p** was isolated (method A: 101 mg, 69%) by column chromatography (light petroleum ether/ethyl acetate, 50:50 to 40:60) as a pale-yellow oil. ¹H NMR (200 MHz, CDCl₃): δ = 7.53 (s, 1 H, 2-H), 7.39–7.23 (m, 3 H, 3'-H, 4'-H, 5'-H), 7.20–7.08 (m, 2 H, 2'-H, 6'-H), 5.46 (s, 2 H, CH₂Ph), 3.80 (s, 3 H, OCH₃), 2.90 (q, *J* = 7.5 Hz, 2 H, CH₃CH₂C), 1.25 (t, *J* = 7.5 Hz, 3 H, CH₃CH₂C) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 161.3 (C=O), 154.2 (C-5), 140.7 (C-2), 136.6 (C-1'), 128.8 (C-3', C-5'), 127.9 (C-4'), 127.1 (C-2', C-6'), 117.8 (C-4), 51.2 (CH₂Ph), 50.6 (OCH₃), 22.8 (CH₃CH₂C), 13.5 (CH₃CH₂C) ppm. MS (EI): *m/z* (%) = 244 (51) [M]⁺, 229 (9), 197 (12), 153 (13), 121 (43), 91 (100), 65 (43). C₁₄H₁₆N₂O₂ (244.12): calcd. C 68.83, H 6.60, N 11.47; found C 69.06, H 6.68, N 11.58.

Methyl 3-Allyl-5-ethyl-3H-imidazole-4-carboxylate (2q): Imidazole **2q** was isolated (method A: 91 mg, 78%) by column chromatography (light petroleum ether/ethyl acetate, 50:50 to 40:60) as a pale-yellow oil. ¹H NMR (200 MHz, CDCl₃): δ = 7.48 (s, 1 H, 2-H), 5.96 (ddt, *J* = 17.0, 10.3, 5.5 Hz, 1 H, NCH₂CH), 5.18 (ddd, *J* = 10.3, 2.4, 1.3 Hz, 1 H, *H*_{cis}), 5.04 (ddd, *J* = 17.0, 2.6, 1.6 Hz, 1 H, *H*_{trans}), 4.85 (dt, *J* = 5.5, 1.3 Hz, 2 H, NCH₂), 3.84 (s, 3 H, CH₃O), 2.87 (q, *J* = 7.5 Hz, 2 H, CH₃CH₂C), 1.22 (t, *J* = 7.5 Hz, 3 H, CH₃CH₂C) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 161.3 (C=O), 154.0 (C-5), 140.3 (C-2), 133.3 (NCH₂CH), 117.7 (NCH₂CH), 117.6 (C-4), 51.2 (NCH₂), 49.4 (OCH₃), 22.7 (CH₃CH₂C), 13.6 (CH₃CH₂C) ppm. MS (EI): *m/z* (%) = 194 (64) [M]⁺, 179 (82), 163 (20), 149 (11), 135 (22), 121 (100), 41 (33). C₁₀H₁₄N₂O₂ (194.11): calcd. C 61.84, H 7.27, N 14.42; found C 61.95, H 7.40, N 14.70.

Ethyl 3-Benzyl-5-propyl-3H-imidazole-4-carboxylate (2r): Imidazole **2r** was isolated (method B: 134 mg, 87%) by column chromatography (light petroleum ether/ethyl acetate, 50:50 to 40:60) as a colorless oil. ¹H NMR (200 MHz, CDCl₃): δ = 7.50 (s, 1 H, 2-H), 7.37–7.20 (m, 3 H, 3'-H, 4'-H, 5'-H), 7.16–7.04 (m, 2 H, 2'-H, 6'-H), 5.44 (s, 2 H, CH₂Ph), 4.24 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 2.86 (t, *J* = 7.4 Hz, 2 H, CH₃CH₂CH₂C), 1.70 (sext., *J* = 7.4 Hz, 2 H, CH₃CH₂CH₂C), 1.28 (t, *J* = 7.1 Hz, 3 H, CH₃CH₂O), 0.95 (t, *J* = 7.4 Hz, 3 H, CH₃CH₂CH₂C) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 161.9 (C=O), 152.8 (C-5), 140.6 (C-2), 136.7 (C-1'), 128.7 (C-3', C-5'), 127.8 (C-4'), 127.0 (C-2', C-6'), 118.4 (C-4), 60.2 (CH₃CH₂O), 50.5 (CH₂Ph), 31.5 (CH₃CH₂CH₂C), 22.8 (CH₃CH₂CH₂C), 14.1 (CH₃CH₂O), 13.9 (CH₃CH₂CH₂C) ppm. MS (EI): *m/z* (%) = 272 (4) [M]⁺, 244 (22), 197 (6), 153 (5), 91 (100), 65 (6). C₁₆H₂₀N₂O₂ (272.15): calcd. C 70.56, H 7.40, N 10.29; found C 70.79, H 7.49, N 10.46.

Ethyl 3-Allyl-5-propyl-3H-imidazole-4-carboxylate (2s): Imidazole **2s** was isolated (method B: 102 mg, 81%) by column chromatography (light petroleum ether/ethyl acetate, 50:50 to 40:60) as a pale-yellow oil. ¹H NMR (200 MHz, CDCl₃): δ = 7.46 (s, 1 H, 2-H), 5.96 (ddt, *J* = 17.0, 10.3, 5.5 Hz, 1 H, NCH₂CH), 5.17 (dd, *J* = 10.3, 1.1 Hz, 1 H, *H*_{cis}), 5.02 (dd, *J* = 17.0, 1.1 Hz, 1 H, *H*_{trans}), 4.85 (d, *J* = 5.5 Hz, 2 H, NCH₂), 4.29 (q, *J* = 7.1 Hz, 2 H, CH₃CH₂O), 2.83 (t, *J* = 7.4 Hz, 2 H, CH₃CH₂CH₂C), 1.67 (sext.,

$J = 7.4$ Hz, 2 H, $\text{CH}_3\text{CH}_2\text{CH}_2\text{C}$), 1.34 (t, $J = 7.1$ Hz, 3 H, $\text{CH}_3\text{CH}_2\text{O}$), 0.93 (t, $J = 7.4$ Hz, 3 H, $\text{CH}_3\text{CH}_2\text{CH}_2\text{C}$) ppm. ^{13}C NMR (50 MHz, CDCl_3): $\delta = 160.9$ (C=O), 152.5 (C-5), 140.1 (C-2), 133.4 (NCH_2CH), 117.6 (2 C: C-4, NCHCH_2), 60.1 ($\text{CH}_3\text{CH}_2\text{O}$), 49.3 (NCH_2), 31.4 ($\text{CH}_3\text{CH}_2\text{CH}_2\text{C}$), 22.7 ($\text{CH}_3\text{CH}_2\text{CH}_2\text{C}$), 14.2 ($\text{CH}_3\text{CH}_2\text{O}$), 13.9 ($\text{CH}_3\text{CH}_2\text{CH}_2\text{C}$) ppm. MS (EI): m/z (%) = 222 (11) $[\text{M}]^+$, 207 (10), 194 (100), 177 (9), 165 (29), 149 (29), 135 (33) 125 (35) 109 (40) 41 (44). $\text{C}_{12}\text{H}_{18}\text{N}_2\text{O}_2$ (222.14): calcd. C 64.84, H 8.16, N 12.60; found C 65.02, H 8.37, N 12.67.

Methyl 3-Benzyl-5-methoxycarbonylmethyl-3H-imidazole-4-carboxylate (2t): Imidazole **2t** was isolated (method B: 97 mg, 59%) by column chromatography (light petroleum ether/ethyl acetate, 50:50 to 70:30) as a whitish solid, m.p. 68–71 °C. ^1H NMR (200 MHz, CDCl_3): $\delta = 7.55$ (s, 1 H, 2-H), 7.42–7.23 (m, 3 H, 3'-H, 4'-H, 5'-H), 7.21–7.10 (m, 2 H, 2'-H, 6'-H), 5.48 (s, 2 H, CH_2Ph), 3.96 (s, 2 H, $\text{CH}_2\text{CO}_2\text{CH}_3$), 3.79 (s, 3 H, CH_3O), 3.71 (s, 3 H, CH_3O) ppm. ^{13}C NMR (50 MHz, CDCl_3): $\delta = 170.9$ ($\text{CH}_2\text{C}=\text{O}$), 160.6 (C=O), 144.5 (C-5), 140.8 (C-2), 136.1 (C-1'), 128.9 (C-3', C-5'), 128.1 (C-4'), 127.3 (C-2', C-6'), 119.8 (C-4), 52.0 (CH_2Ph), 51.4 (OCH_3), 50.7 (OCH_3), 35.7 ($\text{CH}_2\text{CO}_2\text{CH}_3$) ppm. MS (EI): m/z (%) = 288 (22) $[\text{M}]^+$, 228 (8), 197 (5), 121 (35), 91 (100), 65 (13). $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_4$ (288.11): calcd. C 62.49, H 5.59, N 9.72; found C 62.80, H 5.40, N 9.96.

Methyl 3-Allyl-5-methoxycarbonylmethyl-3H-imidazole-4-carboxylate (2u): Imidazole **2u** was isolated (method B: 92 mg, 68%) by column chromatography (light petroleum ether/ethyl acetate, 50:50 to 40:60) as a colorless oil. ^1H NMR (200 MHz, CDCl_3): $\delta = 7.55$ (s, 1 H, 2-H), 6.00 (ddt, $J = 17.0$, 10.3, 5.6 Hz, 1 H, NCH_2CH), 5.24 (ddd, $J = 10.3$, 2.3, 1.3 Hz, 1 H, H_{cis}), 5.11 (ddd, $J = 17.0$, 2.5, 1.5 Hz, 1 H, H_{trans}), 3.96 (s, 2 H, $\text{CH}_2\text{CO}_2\text{CH}_3$), 3.84 (s, 3 H, CH_3O), 3.71 (s, 3 H, CH_3O) ppm. ^{13}C NMR (100 MHz, CDCl_3): $\delta = 171.0$ ($\text{CH}_2\text{C}=\text{O}$), 160.6 (C=O), 144.3 (C-5), 140.4 (C-2), 132.9 (NCH_2CH), 119.6 (C-4), 118.2 (NCHCH_2), 52.1 (NCH_2), 51.5 (OCH_3), 49.6 (OCH_3), 35.8 ($\text{CH}_2\text{CO}_2\text{CH}_3$) ppm. MS (EI): m/z (%) = 238 (19) $[\text{M}]^+$, 206 (7), 179 (100), 147 (20), 119 (35), 41 (67). $\text{C}_{11}\text{H}_{14}\text{N}_2\text{O}_4$ (238.10): calcd. C 55.46, H 5.92, N 11.76; found C 55.87, H 5.68, N 12.09.

Methyl 3-Benzyl-5-phenyl-3H-imidazole-4-carboxylate (2v): Imidazole **2v** was isolated (method B: 99 mg, 57%) by column chromatography (light petroleum ether/ethyl acetate, 50:50 to 40:60) as a whitish solid, m.p. 99–101 °C. ^1H NMR (200 MHz, CDCl_3): $\delta = 7.75$ –7.60 (m, 2 H, 2'-H, 6'-H), 7.66 (s, 1 H, 2-H), 7.48–7.27 (m, 6 H, 3'-H, 4'-H, 5'-H, 3''-H, 4''-H, 5''-H), 7.22 (d, $J = 7.8$ Hz, 2 H, 2'-H, 6'-H), 5.54 (s, 2 H, CH_2Ph), 4.18 (q, $J = 7.1$ Hz, 2 H, $\text{CH}_3\text{CH}_2\text{O}$), 1.12 (t, $J = 7.1$ Hz, 3 H, $\text{CH}_3\text{CH}_2\text{O}$) ppm. ^{13}C NMR (50 MHz, CDCl_3): $\delta = 160.7$ (C=O), 149.6 (C-5), 141.0 (C-2), 136.4 (C-1'), 134.3 (C-1''), 129.5 (C-2'', C-6''), 128.9 (2 C), 128.09, 128.06, 127.6 (C-2', C-6'), 127.2 (2 C), 118.6 (C-4), 60.7 ($\text{CH}_3\text{CH}_2\text{O}$), 50.8 (CH_2Ph), 13.8 ($\text{CH}_3\text{CH}_2\text{O}$) ppm. MS (EI): m/z (%) = 306 (44) $[\text{M}]^+$, 260 (7), 233 (11), 171 (6), 91 (100), 65 (14). $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_2$ (306.14): calcd. C 74.49, H 5.92, N 9.14; found C 74.77, H 5.77, N 9.33.

Methyl 3-Allyl-5-phenyl-3H-imidazole-4-carboxylate (2w): Imidazole **2w** was isolated (method B: 90 mg, 62%) by column chromatography (light petroleum ether/ethyl acetate, 70:30 to 40:60) as a pale-yellow oil. ^1H NMR (200 MHz, CDCl_3): $\delta = 7.78$ –7.59 (m, 3 H, 2'-H, 6'-H, 2-H), 7.50–7.30 (m, 3 H, 3'-H, 4'-H, 5'-H), 6.06 (ddt, $J = 17.0$, 11.0, 5.5 Hz, 1 H, NCH_2CH), 5.28 (dd, $J = 11.0$, 0.9 Hz, 1 H, H_{cis}), 5.17 (dd, $J = 17.0$, 0.9 Hz, 1 H, H_{trans}), 4.95 (d, $J = 5.5$ Hz, 2 H, NCH_2), 4.24 (q, $J = 7.1$ Hz, 2 H, $\text{CH}_3\text{CH}_2\text{O}$), 1.20 (t, $J = 7.1$ Hz, 3 H, $\text{CH}_3\text{CH}_2\text{O}$) ppm. ^{13}C NMR

(50 MHz, CDCl_3): $\delta = 160.7$ (C=O), 149.4 (C-5), 140.5 (C-2), 134.4 (C-1'), 133.2 (NCH_2CH), 129.5 (C-3', C-5'), 128.0 (C-4'), 127.5 (C-2', C-6'), 118.4 (C-4), 118.1 (CHCH_2), 60.6 ($\text{CH}_3\text{CH}_2\text{O}$), 49.6 (CH_2Ph), 13.8 ($\text{CH}_3\text{CH}_2\text{O}$) ppm. MS (EI): m/z (%) = 256 (100) $[\text{M}]^+$, 209 (43), 183 (86), 171 (27), 89 (43), 41 (44). $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_2$ (256.12): calcd. C 70.29, H 6.29, N 10.93; found C 70.65, H 6.02, N 10.83.

Supporting Information (see footnote on the first page of this article): Experimental procedure for the preparation of noncommercially available aldehydes (and spectroscopic data thereof) used for the synthesis of imidazole-4-carboxylates **2l–n** and ^1H and ^{13}C NMR spectra for DDs **1c–f** and imidazoles **2a–w**.

Acknowledgments

Financial support from the Ministero dell'Università, dell'Istruzione e della Ricerca (PRIN 2007) and by the US National Institutes of Health (grant GM63815 to B. K. Shoichet and F. P.) is gratefully acknowledged. We are indebted to Prof. Livio Brasili (Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia) for kindly allowing use of the microwave reactor and to Fondazione Cassa di Risparmio di Modena for refurbishing the NMR and MS facilities.

- [1] For general reviews on microwave-assisted organic synthesis, see: a) S. Caddick, R. Fitzmaurice, *Tetrahedron* **2009**, *65*, 3325–3355; b) C. O. Kappe, D. Dallinger, S. S. Murphree (Eds.), *Practical Microwave Synthesis for Organic Chemists: Strategies, Instruments, and Protocols*, Wiley-VCH, Weinheim, **2009**; c) A. Loupy (Ed.), *Microwaves in Organic Synthesis*, 2nd ed., Wiley-VCH, Weinheim, **2006**; d) M. C. Bagley, M. C. Lubinu, *Top. Heterocycl. Chem.* **2006**, *1*, 31–58; e) P. Lidström, J. P. Tierney (Eds.), *Microwave-Assisted Organic Synthesis*, Blackwell, Oxford, **2005**; f) P. Lidström, J. Tierney, B. Wathey, J. Westman, *Tetrahedron* **2001**, *57*, 9225–9283; g) L. Perreux, A. Loupy, *Tetrahedron* **2001**, *57*, 9199–9223.
- [2] For reviews on the use of microwave heating in cycloadditions, see: a) M. Pineiro, T. M. V. D. Pinho e Melo, *Eur. J. Org. Chem.* **2009**, 5287–5307; b) K. Bougrin, M. Soufiaoui, G. Bashiardes in *Microwaves in Organic Synthesis*, 2nd ed. (Ed.: A. Loupy), Wiley-VCH, Weinheim, **2006**, pp. 524–578; c) A. de la Hoz, A. Díaz-Ortiz, F. Langa in *Microwaves in Organic Synthesis* (Ed.: A. Loupy), Wiley-VCH, Weinheim, **2002**, pp. 295–343.
- [3] For selected examples, see: a) A. Arrieta, D. Otaegui, A. Zubia, F. P. Cossio, Á. Díaz-Ortiz, A. de la Hoz, M. A. Herrero, P. Prieto, C. Foces-Foces, J. L. Pizarro, M. I. Arriortua, *J. Org. Chem.* **2007**, *72*, 4313–4322; b) G. Bashiardes, I. Safir, A. S. Mohamed, F. Barbot, J. Laduranty, *Org. Lett.* **2003**, *5*, 4915–4918; c) N. S. Wilson, C. R. Sarko, G. P. Roth, *Tetrahedron Lett.* **2001**, *42*, 8939–8941.
- [4] For reviews on the chemistry of DDs, see: a) O. A. Attanasi, L. De Crescentini, G. Favi, P. Filippone, F. Mantellini, F. R. Perrulli, S. Santeusano, *Eur. J. Org. Chem.* **2009**, 3109–3127; b) O. A. Attanasi, L. De Crescentini, P. Filippone, F. Mantellini, S. Santeusano, *Arkivoc* **2002**, *xi*, 274–292; for recent examples of DDs as versatile building blocks to a variety of heterocycles, see: c) O. A. Attanasi, G. Favi, G. Giorgi, F. Mantellini, V. Karapetyan, P. Langer, *Tetrahedron* **2009**, *65*, 5456–5461; d) O. A. Attanasi, L. De Crescentini, G. Favi, P. Filippone, G. Giorgi, F. Mantellini, G. Moscatelli, M. S. Behalo, *Org. Lett.* **2009**, *11*, 2265–2268; e) O. A. Attanasi, S. Berretta, L. De Crescentini, G. Favi, G. Giorgi, F. Mantellini, *Adv. Synth. Catal.* **2009**, *351*, 715–719; f) O. A. Attanasi, G. Favi, P. Filippone, F. R. Perrulli, S. Santeusano, *Org. Lett.* **2009**, *11*, 309–312.
- [5] O. A. Attanasi, P. Davoli, G. Favi, P. Filippone, A. Forni, G. Moscatelli, F. Prati, *Org. Lett.* **2007**, *9*, 3461–3464.

- [6] O. A. Attanasi, E. Caselli, P. Davoli, G. Favi, F. Mantellini, C. Ori, F. Prati, *Org. Lett.* **2009**, *11*, 2840–2843.
- [7] a) T. M. V. D. Pinho e Melo, *Eur. J. Org. Chem.* **2006**, 2873–2888; b) W. Eberbach in *Science of Synthesis: Houben-Weyl Methods of Molecular Transformations* (Eds.: A. Padwa, D. Bellus), Thieme, Stuttgart, **2004**, vol. 27, pp. 441–498.
- [8] For general reviews on azomethine ylides, see: a) G. Pandey, P. Banerjee, S. R. Gadre, *Chem. Rev.* **2006**, *106*, 4484–4517; b) M. Bonin, A. Chauveau, L. Micouin, *Synlett* **2006**, 2349–2363; c) C. Nájera, J. M. Sansano, *Angew. Chem. Int. Ed.* **2005**, *44*, 6272–6276; d) I. Coldham, R. Hufton, *Chem. Rev.* **2005**, *105*, 2765–2809; e) L. M. Harwood, R. J. Vickers in *The Chemistry of Heterocyclic Compounds: Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry toward Heterocycles and Natural Products* (Eds.: A. Padwa, W. H. Pearson), Wiley, New York, **2002**, vol. 59, pp. 169–252; f) K. V. Gothelf, K. A. Jørgensen, *Chem. Rev.* **1998**, *98*, 863–909.
- [9] a) M. Xia, Y.-d. Lu, *J. Mol. Catal. A* **2007**, *265*, 205–208; b) M. Kidwai, S. Saxena, Ruby, S. Rastogi, *Bull. Korean Chem. Soc.* **2005**, *26*, 2051–2053; c) E. Gelens, F. J. J. De Kanter, R. F. Schmitz, L. A. J. M. Sliedregt, B. J. Van Steen, C. G. Kruse, R. Leurs, M. B. Groen, R. V. A. Orru, *Mol. Diversity* **2006**, *10*, 17–22; d) N. Zhao, Y.-L. Wang, J.-Y. Wang, *J. Chin. Chem. Soc. (Taipei, Taiwan)* **2005**, *52*, 535–538; e) Y. Xu, L.-F. Wan, H. Salehi, W. Deng, Q.-X. Guo, *Heterocycles* **2004**, *63*, 1613–1618; f) R. B. Sparks, A. P. Combs, *Org. Lett.* **2004**, *6*, 2473–2475; g) S. E. Wolkenberg, D. D. Wisnoski, W. H. Leister, Y. Wang, Z. Zhao, C. W. Lindsley, *Org. Lett.* **2004**, *6*, 1453–1456; h) Ş. Demirayak, U. A. Mohsen, K. Güven, *Boll. Chim. Farm.* **2002**, *141*, 443–446; i) A. Ya. Ustyatinsky, Yu. L. Khmel'nitsky, *Tetrahedron Lett.* **2000**, *41*, 5031–5034.
- [10] a) L. Nagarapu, S. Apuri, S. Kantevari, *J. Mol. Catal. A* **2007**, *266*, 104–108; b) Y. Xu, Y.-z. Liu, L. Rui, L. Liu, Q.-x. Guo, *Heterocycles* **2004**, *63*, 87–93.
- [11] For reviews on the synthesis of imidazoles, see: a) M. R. Grimmett in *Science of Synthesis* (Ed.: R. Neier), Thieme, Stuttgart, **2002**, vol. 12, pp. 325–328; b) K. Ebel in *Methoden der Organischen Chemie (Houben-Weyl)* (Ed.: E. Schaumann), Thieme, Stuttgart, **1994**, vol. E8c, pp. 1–192.
- [12] a) O. A. Attanasi, P. Filippone, A. Mei, F. Serra-Zanetti, *Synth. Commun.* **1986**, *16*, 343–351; b) O. A. Attanasi, P. Filippone, A. Mei, S. Santeusano, *Synthesis* **1984**, 671–672.
- [13] Q. Liu, E. M. Ferreira, B. M. Stoltz, *J. Org. Chem.* **2007**, *72*, 7352–7358.

Received: March 31, 2010
Published Online: June 8, 2010